RE:RE:RE:Phase 1/2 AMBUSH Trial The GSK antibody-drug conjugate (ADC) Blenrep didn’t outdo Bristol Myers Squibb’s Pomalyst and low-dose dexamethasone at slowing disease progression or death, the company said Monday.
The DREAMM-3 trial flop is a blow to GSK’s oncology ambitions; the British pharma has projected Blenrep could reach more than 3 billion pounds sterling in peak sales. And it puts Blenrep’s accelerated approval in multiple myeloma in danger.
The study found Blenrep had no notable effects on progression-free survival, even though patients who got the GSK drug lived longer without disease progression at the median, going 11.2 months versus seven months. The discrepancy suggests a possible worsening of effect in the Blenrep arm after the median point.
https://www.fiercepharma.com/pharma/gsks-car-t-rival-blenrep-fails-multiple-myeloma-trial-endangering-fda-accelerated-approval